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The International Committee of Medical Journal 
Editors (ICMJE) believes that there is an ethical 
obligation to responsibly share data generated by 
interventional clinical trials because participants 
have put themselves at risk. In a growing 
consensus, many funders around the world-
foundations, government agencies, and industry-
now mandate data sharing. Here we outline 
ICMJE’s proposed requirements to help meet this 
obligation. We encourage feedback on the 
proposed requirements. Anyone can provide 
feedback at www.icmje.org by 18 April 2016. 
The ICMJE defines a clinical trial as any 
research project that prospectively assigns people 
or a group of people to an intervention, with or 
without concurrent comparison or control groups, 
to study the cause-and-effect relationship 
between a health-related intervention and a health 
outcome. Further details may be found in the 
Recommendations for the Conduct, Reporting, 
Editing and Publication of Scholarly Work in 
Medical Journals at www.icmje.org. 
As a condition of consideration for 
publication of a clinical trial report in our 
member journals, the ICMJE proposes to require 
authors to share with others the deidentified 
individual-patient data (IPD) underlying the 
results presented in the article (including tables, 
figures, and appendices or supplementary 
material) no later than 6 months after publication. 
The data underlying the results are defined as the 
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including necessary metadata. This requirement 
will go into effect for clinical trials that begin to 
enroll participants beginning 1 year after the 
ICMJE adopts its data-sharing requirements.*  
Enabling responsible data sharing is a 
major endeavor that will affect the fabric of how 
clinical trials are planned and conducted and how 
their data are used. By changing the requirements 
of the manuscripts we will consider for 
publication in our journals, editors can help foster 
this endeavor. As editors, our direct influence is 
logically, and practically, limited to those data 
underpinning the results and analyses we publish 
in our journals.  
The ICMJE also proposes to require that 
authors include a plan for data sharing as a 
component of clinical trial registration. This plan 
must include where the researchers will house the 
data and, if not in a public repository, the 
mechanism by which they will provide others 
access to the data, as well as other data-sharing 
plan elements outlined in the 2015 Institute of 
Medicine Report (e.g., whether data will be freely 
available to anyone upon request or only after 
application to and approval by a learned 
intermediary, whether a data use agreement will 
be required) (1). ClinicalTrials.gov has added an 
element to its registration platform to collect 
data-sharing plans. We encourage other trial 
registries to similarly incorporate mechanisms for 
the registration of data-sharing plans. Trialists 
who want to publish in ICMJE member journals 
(or nonmember journals that choose to follow 
these recommendations) should choose a registry 
that includes a data-sharing plan element as a 
specified registry item or allows for its entry as a 
free-text statement in a miscellaneous registry 
field. As a condition of consideration for 
publication in our member journals, authors will 
be required to include a description of the data-
sharing plan in the submitted manuscript. Authors 
may choose to share the deidentified IPD 
underlying the results presented in the article 
under less restrictive, but not more restrictive, 
conditions than were indicated in the registered 
data-sharing plan.  
ICMJE already requires the prospective 
registration of all clinical trials prior to 
enrollment of the first participant. This 
requirement aims, in part, to prevent selective 
publication and selective reporting of research 
outcomes, and to prevent unnecessary duplication 
of research effort. Including a commitment to a 
data-sharing plan is a logical addition to trial 
registration that will further each of these goals. 
Prospective trial registration currently includes 
documenting the planned primary and major 
secondary end points to be assessed, which 
enables identification of incomplete reporting as 
well as post hoc analyses. Declaring the plan for 
sharing data prior to their collection will further 
enhance transparency in the conduct and 
reporting of clinical trials by exposing when data 
availability following trial completion differs 
from prior commitments.  
Sharing clinical trial data, including 
deidentified IPD, requires planning to ensure 
appropriate ethics committee or institutional 
review board approval and the informed consent 
of study participants. Accordingly, we will defer 
these requirements for 1 year to allow 
investigators, trial sponsors, and regulatory 
bodies time to plan for their implementation.  
Just as the confidentiality of trial 
participants must be protected (through the 
deidentification of IPD), and the needs of those 
reasonably requesting data met (through the 
provision of useable data), the reasonable rights 
of investigators and trial sponsors must also be 
protected. ICMJE proposes the following to 
safeguard these rights. First, ICMJE editors will 
not consider the deposition of data in a registry to 
constitute prior publication. Second, authors of 
secondary analyses using these shared data must 
attest that their use was in accordance with the 
terms (if any) agreed to upon their receipt. Third, 
they must reference the source of the data using a 
unique identifier of a clinical trial’s data set to 
provide appropriate credit to those who generated 
it and allow searching for the studies it has 
supported. Fourth, authors of secondary analyses 
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previous analyses. In addition, those who 
generate and then share clinical trial data sets 
deserve substantial credit for their efforts. Those 
using data collected by others should seek 
collaboration with those who collected the data. 
However, because collaboration will not always 
be possible, practical, or desired, an alternative 
means of providing appropriate credit needs to be 
developed and recognized in the academic 
community. We welcome ideas about how to 
provide such credit.  
Data sharing is a shared responsibility. 
Editors of individual journals can help foster data 
sharing by changing the requirements of the 
manuscripts they will consider for publication in 
their journals. Funders and sponsors of clinical 
trials are in a position to support and ensure 
adherence to IPD sharing obligations. If journal 
editors become aware that IPD sharing 
obligations are not being met, they may choose to 
request additional information; to publish an 
expression of concern; to notify the sponsors, 
funders, or institutions; or in certain cases, to 
retract the publication. 
In the rare situation in which compliance with 
these requirements is impossible, editors may 
consider authors’ requests for exceptions. If an 
exception is made, the reason(s) must be 
explained in the publication.  
Sharing data will increase confidence and 
trust in the conclusions drawn from clinical trials. 
It will enable the independent confirmation of 
results, an essential tenet of the scientific process. 
It will foster the development and testing of new 
hypotheses. Done well, sharing clinical trial data 
should also make progress more efficient by 
making the most of what may be learned from 
each trial and by avoiding unwarranted repetition. 
It will help to fulfill our moral obligation to study 
participants, and we believe it will benefit 
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Feedback may be posted at www.icmje.org by 18 April 2016.  
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